Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P08865
UPID:
RSSA_HUMAN
Alternative names:
37 kDa laminin receptor precursor; 37/67 kDa laminin receptor; 40S ribosomal protein SA; 67 kDa laminin receptor; Colon carcinoma laminin-binding protein; Laminin receptor 1; Laminin-binding protein precursor p40; Multidrug resistance-associated protein MGr1-Ag; NEM/1CHD4
Alternative UPACC:
P08865; P11085; P12030; Q16471; Q6IPD1; Q6IPD2; Q6NSD1; Q6NXQ8; Q86VC0
Background:
Small ribosomal subunit protein uS2, known as the 40S ribosomal protein SA, plays a crucial role in the assembly and stability of the 40S ribosomal subunit. It is essential for processing the 20S rRNA-precursor into mature 18S rRNA, a key step in ribosomal subunit maturation. Additionally, it serves as a cell surface receptor for laminin, influencing cell adhesion, signaling pathways, and tissue morphogenesis. Its interaction with various pathogens, including Adeno-associated viruses, Dengue virus, and the pathogenic prion protein, highlights its significance in microbial infection.
Therapeutic significance:
Given its involvement in isolated congenital asplenia, a rare and life-threatening condition, understanding the role of Small ribosomal subunit protein uS2 could open doors to potential therapeutic strategies. Its pivotal role in ribosomal function and cell surface interactions makes it a target for addressing severe bacterial infections and possibly influencing tissue morphogenesis and disease outcomes.